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Abstract
Background: Differentiating psychogenic parkinsonism from neurodegenerative Parkinson’s disease (PD) with psychogenic features is a diagnostic challenge.
Case report: We report a detailed longitudinal clinical description of three cases presenting with suspected psychogenic parkinsonism. Dopamine transporter
single-photon emission computed tomography (DAT-SPECT) was used as a supplemental diagnostic study and influenced clinical management.
Discussion: DAT-SPECT quantified the integrity of the striatal dopaminergic system in these cases of clinically uncertain parkinsonism and supported clinical
decision-making.
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Introduction
123I-labled 2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl)-
nortropane ([123I]-FP-CIT) single-photon emission computed tomo-
graphy (SPECT) imaging was approved for clinical use in the United
States in 2011 for visualization of striatal dopamine transporter activity
to identify presynaptic dopaminergic parkinsonism.1 Although some
physicians question its clinical utility,1 dopamine transporter SPECT
imaging (DAT-SPECT) is increasingly recognized as having practical
relevance.2 To add to the growing number of uses, we describe a
specific scenario where management of three parkinsonian patients
with psychogenic features was influenced by imaging. While previous
work3 addressed the role of DAT-SPECT imaging in evaluating
psychogenic parkinsonism, to our knowledge, ours is the first
demonstration that this imaging tool markedly influenced clinical
management in a cohort of three patients.
Distinguishing ‘‘pure’’ psychogenic parkinsonism from neurodegen-
erative Parkinson’s disease (PD) with concurrent psychogenic features
is a diagnostic dilemma. Correct diagnosis is relevant to clinical
management in preventing pure psychogenic patients from exposure
to unwarranted anti-parkinsonian (anti-PD) medications, while
providing adequate treatment to those with neurodegenerative PD
complicated by psychogenic overlay. While clinical exam and tremor
electrophysiology can document psychogenic features, they generally
cannot inform about concomitant neurodegenerative disease. In our
cohort, we demonstrate that DAT-SPECT is a useful diagnostic tool
that can serve to distinguish pure psychogenic parkinsonism from
neurodegenerative PD with psychogenic overlay and thus guide
clinical management.
Case report
A 39-year-old male (Case 1) was referred for evaluation of left hand
rest tremor, rigidity, and poor fine motor coordination. On exam, he
had mild amplitude left hand rest and postural tremor with a semi-
purposeful appearance. The tremor was distractible, suggestible, and
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entrainable. There was mild left arm cogwheel rigidity and
bradykinesia. Anti-PD medications were started 24 months after
symptom onset, with rasagiline 1 mg daily first, then ropinirole 6 mg
daily. On medications, he reported minimal improvement with
gradual worsening of his left hand tremor and fine motor coordination.
Despite reported worsening in left hand function, follow-up examina-
tions demonstrated an ability to complete complex fine motor tasks.
While psychogenic features were unequivocally confirmed during
examination, underlying neurodegenerative parkinsonism could not be
excluded. [123I]-FP-CIT SPECT (Figure 1, Table 1) was obtained and
showed moderate-to-severe dopamine transporter deficit. Levodopa
therapy was subsequently started with improved symptoms.
A 36-year-old female (Case 2) presented for evaluation of
parkinsonism. Four years before presentation, she developed micro-
graphia, right arm tremor, and rigidity and was diagnosed with PD at
another institution. On initial evaluation, she was already prescribed
daily doses of rasagiline 1 mg, carbidopa/levodopa 350 mg, and
ropinirole 2 mg. On exam, she had mild right arm rest/postural hand
tremor and mild-to-moderate cogwheel rigidity bilaterally. Her rigidity
and tremor were distractible. She had moderate bradykinesia
bilaterally with variability. With this presentation, psychogenic
parkinsonism was strongly suspected, but underlying neurodegenera-
tive parkinsonism could not be excluded. Her anti-PD medications
were continued based on her reported symptomatic relief; however,
reported side effects and questions about the variability of benefits
created concern of unnecessary drug exposure if she did not
have underlying neurodegenerative disease. [123I]-FP-CIT SPECT
(Figure 1, Table 1) was obtained and revealed moderate-to-severe
dopamine transporter deficit. With this result, her anti-PD medications
were titrated to adequate symptomatic control.
Figure 1. [123I]-FP-CIT SPECT scan images. Case 1, Case 2, and Case 3, respectively. The images were interpreted by a nuclear medicine physician (Z.S.) using
established criteria and were quantitatively analyzed using the BRASS software (Hermes Medical Solutions, Stockholm Sweden). The quantification program is objective
since it is entirely operator independent.
Table 1. Striatal Binding of Cases 1, 2, and 3.
Striatal Binding Case 1 Case 2 Case 3 Healthy Controls (mean¡SD, n57)
Right caudate 1.01 1.51 1.86 1.94¡0.56
Left caudate 1.10 0.84 1.85 1.98¡0.43
Right putamen 0.56 0.81 1.83 1.75¡0.38
Left putamen 0.60 0.40 1.70 1.83¡0.41
Abbreviation: SD, Standard Deviation.
This parameter was calculated as a specific binding ratio relative to the occipital lobe as a reference tissue. The striatal specific binding ratio is calculated as: (S-O)/O.
Where, S is activity in the striatum (caudate or putamen) and O is the activity in the occipital lobe. Any positive number indicates higher binding in the striatum than in
the reference region. The reference normal striatal binding values were obtained in seven healthy controls.
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A 41-year-old male (Case 3) presented for evaluation of parkinson-
ism. Initial symptoms included foot dystonia and right arm tremor. He
had been diagnosed with parkinsonism 1 year prior and was on
600 mg of carbidopa/levodopa and 800 mg of entacapone daily. On
examination, he had semi-purposeful right arm global tremor with
variability in frequency. His tremor was distractible and decreased in
amplitude when the opposite side of the body was examined. He
displayed oppositional rigidity in his lower extremities. There was
pseudoakinesia with deliberate slowness on finger-taps. We suspected
psychogenic parkinsonism but could not rule out underlying
neurodegenerative PD. Diagnosis of dystonic tremor was considered
but was lower on the differential due to the prominent elements of
parkinsonism with psychogenic features. Diagnostic work-up included
[123I]-FP-CIT SPECT (Figure 1, Table 1), which was negative. In
light of this result, we started the process of carefully tapering his anti-
PD medications. He has been connected with a psychiatrist with
expertise in psychogenic movement disorders.
For each case, the images were interpreted by a nuclear medicine
physician (Z.S.) using established criteria and were quantitatively
analyzed using BRASS software.4,5
Discussion
Neurodegenerative PD with psychogenic overlay can prove a
diagnostic quandary. Electrophysiological tremor recording is useful in
proving the presence of a psychogenic tremor but cannot unequi-
vocally identify individuals with underlying neurodegenerative PD,
especially in non-tremor predominant cases. In contrast, DAT-SPECT
can quantify with high sensitivity presynaptic striatal dopaminergic
deficit, which is not present in pure psychogenic disease but is expected
in cases of neurodegenerative PD even if complicated by a marked
psychogenic overlay. While a previous study3 examined DAT-SPECT
as a diagnostic tool in psychogenic parkinsonism, we highlight the
impact of DAT-SPECT in influencing treatment decisions in the
specific scenario where ‘‘pure’’ psychogenic parkinsonism cannot be
distinguished from neurodegenerative PD with psychogenic features by
clinical exam alone.
Psychogenic parkinsonism accounts for approximately 10% of all
cases of psychogenic movement disorders.6 It can mimic idiopathic PD
and proves a diagnostic challenge even for experienced movement
disorder neurologists. In contrast to idiopathic PD, individuals with
psychogenic parkinsonism are more likely to display variability in
tremor frequency/rhythm, pseudoakinesia with exaggerated slowness,
and oppositional rigidity without true cogwheeling.3 Features of
distractibility, suggestibility, and entrainment of tremor are also
characteristic.
When diagnostic uncertainty arises in cases of suspected neurode-
generative PD with psychogenic features, treatment decisions may be
difficult. Anti-PD medication trials are often attempted but may be
difficult to interpret due to the placebo effect and variability of patient
response. Prolonged medication trials in patients with ‘‘pure’’
psychogenic parkinsonism are potentially harmful and may unneces-
sarily increase health care spending. DAT-SPECT showing striatal
dopaminergic deficit can support a diagnosis of PD in the right clinical
context, thus improving diagnostic confidence and supporting early
institution of anti-PD medications, which has been shown to be
beneficial in previous studies.7
The diagnostic accuracy of DAT-SPECT has been evaluated. Two
multicenter phase III studies serving as the basis for DAT-SPECT
approval in the United States were reported so have DAT-SPECT
sensitivities of 79% and 97% and specificities of 97% and 98%,
respectively.1 Another study of 743 cases found low error rates of
DAT-SPECT in PD diagnosis: five false-positives and two false-
negatives with a sensitivity and specificity of 99.4% and 98.6%,
respectively.8 Notably, the diagnostic accuracy of DAT-SPECT in
these studies was determined using clinical diagnosis as the ‘‘gold
standard.’’ Without pathological data, the certainty of the clinical
diagnosis made in these studies is unknown. The diagnostic challenge
in early PD is demonstrated in previous clinical trials.8 For example, in
the Earlier versus Later Levodopa Therapy in Parkinson Disease
(ELLDOPA) study, 15% of subjects initially diagnosed as PD were
later re-classified as subjects without evidence of dopaminergic deficit
(SWEDDs) after SPECT imaging.7,8
DAT-SPECT provides quantification of the presynaptic dopami-
nergic transporter system rather than a specific diagnosis. Diagnostic
accuracy is improved by narrowing the clinically developed differential
diagnoses to neurodegenerative versus non-neurodegenerative parkin-
sonian syndromes. A negative DAT-SPECT can support a variety
of diagnoses in the right clinical context, including psychogenic
parkinsonism, dopa-responsive dystonia associated with parkinsonism,
essential tremor, vascular parkinsonism, or drug-induced parkinson-
ism. On the other hand, a positive DAT-SPECT could indicate a
diagnosis of PD, multiple system atrophy (MSA), progressive supra-
nuclear palsy (PSP), or corticobasal degeneration (CBD). Admittedly,
DAT-SPECT is unreliable in distinguishing PD from other neurode-
generative parkinsonian disorders. However, in our particular cohort,
no significant consideration of Parkinson Plus syndromes could be
made on clinical grounds. Additionally, a negative DAT-SPECT does
not exclude metabolic causes of dopa-responsive dystonia associated
with parkinsonism, such as Guanosine Triphosphate (GTP) cyclohy-
drolase 1 deficiency. While DAT-SPECT may not be appropriate in
every scenario, combining DAT-SPECT results with clinical findings
can improve diagnostic accuracy and guide treatment in clinically
uncertain cases.
The cost effectiveness of DAT-SPECT factors into the utility of
the scan. A review on the economic impact of DAT-SPECT showed
reduced overall cost of care in cases of clinically uncertain
parkinsonian syndromes.8 In these cases, cost savings were achieved
by avoiding unnecessary medications and improving time spent on
appropriate management.8 While accounting for the long-term cost
benefits of the DAT-SPECT, risks associated with obtaining the scan
should also be recognized. De la Fuente-Fernandez1 reported a low
radiation effective dose of 3.94 mSv for DAT-SPECT, which is similar
to the radiation exposure of a computed tomography (CT) scan of the
neck (4 mSv). Estimated cancer risk based on these values ranged from
Utility of SPECT in Psychogenic Parkinsonism Umeh CC, Szabo Z, Pontone GM, et al.
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services3
1 in 5,000 to 7,500 depending on age.1,8 Risk-benefit assessments are
key when considering DAT-SPECT as an adjunctive study.
Notably, Case 3 could be classified under the broad category of
SWEDDs. The term SWEDDs encompasses a heterogeneous group of
diagnoses with the unifying criteria of features of parkinsonism with
normal dopaminergic imaging.9 SWEDDs can have similar phenom-
enological features as in neurodegenerative PD and have been
identified in previous PD clinical trials based on normal dopaminergic
imaging.10 There is no consistent evidence to suggest SWEDDs
require dopaminergic therapy.
The negative DAT-SPECT in Case 3 taken together with the
prominent psychogenic features and lack of supportive evidence for
alternative diagnoses (drug-induced PD, dystonic tremor), led to the
diagnosis of psychogenic parkinsonism. Counseling was provided
to Case 3 to carefully explain how the diagnosis of psychogenic
parkinsonism was reached (based on the normal DAT-SPECT results
in addition to clinical exam features), and discussion ensued
regarding the best management, including referral to psychiatric
counseling and tapering off anti-PD medications. In all three cases, a
critical decision-making point was reached where it was unclear that
continuing anti-PD medications was appropriate. This was explained
during follow-up visits as the basis for ordering the DAT-SPECT
scan, to improve diagnostic accuracy and decide on best medical
therapy. In Cases 1 and 2, DAT-SPECT findings were useful in
narrowing the differential diagnoses to causes of neurodegenerative
parkinsonism, with PD as the most probable diagnosis based on the
clinical presentations. Cases 1 and 2 did not have phenotypic features
supportive of other neurodegenerative parkinsonian syndromes.
DAT-SPECT was clinically meaningful in these cases as it increased
diagnostic confidence leading to more aggressive anti-PD manage-
ment in the first two cases and appropriate referral for psychiatric
counseling for the third case.
The emergence of DAT-SPECT introduced a supplemental
diagnostic tool that can quantify nigrostriatal dopaminergic system
integrity. Consideration of the clinical utility of DAT-SPECT should
include its potential impact on treatment decisions in clinically
uncertain cases, diagnostic accuracy, cost effectiveness, radiation
exposure risk, and on patients’ expectations about a timely diagnosis.
When applied in our cases of clinically uncertain psychogenic
parkinsonism, DAT-SPECT improved diagnostic certainty and helped
support treatment decisions.
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